OMERS ADMINISTRATION Corp Purchases 68,678 Shares of Pfizer Inc. $PFE

OMERS ADMINISTRATION Corp boosted its position in Pfizer Inc. (NYSE:PFE) by 22.3% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 375,974 shares of the biopharmaceutical company’s stock after purchasing an additional 68,678 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Pfizer were worth $9,053,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Keb Asset Management LLC bought a new stake in Pfizer during the second quarter worth $26,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. grew its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $27.97 on Tuesday. The firm’s 50 day moving average is $25.34 and its 200 day moving average is $26.26. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a market capitalization of $159.41 billion, a P/E ratio of 36.80 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on PFE shares. Citigroup boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Wolfe Research reissued an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a research note on Tuesday, June 9th. Finally, BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.